Fibromyalgia patients taking pregabalin had significant improvements in sleep and decreased daily pain, according to a new study published in the April 2012 issue of Arthritis Care & Research.
Fibromyalgia patients taking pregabalin had significant improvements in sleep and decreased daily pain, according to a new study.
Published in the April 2012 issue of Arthritis Care & Research, the study was led by Thomas Roth, PhD, of the Sleep Disorders and Research Center, the Henry Ford Health System in Detroit, Mich.
Researchers conducted a randomized, double-blind, placebo-controlled crossover study using polysomonographic (PSG) measures of sleep. Fibromyalgia patients taking 300 mg to 450 mg of pregabalin per day showed a reduction in PSG-determined wake versus sleep onset of -19.2 minutes versus placebo at -26.7 minutes. Patients’ pain score also improved with pregabalin by -.52.
The researchers also found modest but significant correlations between PSG sleep assessments and pain and sleep quality. “Patients with fibromyalgia treated with pregabalin had statistically significant and meaningful improvements in sleep,” Roth wrote in the study.
In addition, pregabalin was generally well tolerated, although 30.4% of patients taking pregabalin reported dizziness, 20.5% experienced somnolence, and 8.9% of fibromyalgia patients had headaches with pregabalin.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.